A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development - PubMed (original) (raw)
Comparative Study
. 2000 Feb 21;19(8):1052-8.
doi: 10.1038/sj.onc.1203270.
Affiliations
- PMID: 10713689
- DOI: 10.1038/sj.onc.1203270
Comparative Study
A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development
D J Jerry et al. Oncogene. 2000.
Abstract
Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53(null) mice. This has led to the suggestion that absence of p53 alone is not sufficient for induction of mammary tumors. However, early death of p53(null) mice from thymic lymphomas may obscure tumor phenotypes that would develop later. Therefore, p53(null) mammary epithelium was transplanted into cleared mammary fat pads of wild type p53 BALB/c hosts to allow long-term analysis of mammary tumor phenotypes. Five treatments were compared for their effects on tumor incidence in hosts bearing transplants of p53(null) and p53wt mammary epithelium. The treatment groups were: (1) untreated; (2) continuous hormone stimulation with pituitary isografts; (3) multiple pregnancies; (4) DMBA alone; and (5) DMBA+pituitary isografts. The tumor incidences in p53(null) vs p53wt mammary transplants for each treatment group were 62% vs 0%, 100% vs 0%, 68% vs 0%, 60% vs 4% and 91% vs 14%, respectively. The mammary tumors that developed in the p53(null) mammary epithelium were all adenocarcinomas and were frequently aneuploid. These data demonstrate that the absence of p53 is sufficient to cause development of mammary tumors and that hormonal stimulation enhances the tumorigenicity of p53(null) mammary epithelium to a greater extent than DMBA exposure alone. This model provides an in situ approach to examine the molecular basis for the role of p53 in the regulation of mammary tumorigenesis.
Similar articles
- Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS. Zelazny E, et al. Exp Mol Pathol. 2001 Jun;70(3):183-93. doi: 10.1006/exmp.2001.2357. Exp Mol Pathol. 2001. PMID: 11417997 - A transgenic mouse model for mammary carcinogenesis.
Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM. Li B, et al. Oncogene. 1998 Feb 26;16(8):997-1007. doi: 10.1038/sj.onc.1201621. Oncogene. 1998. PMID: 9519874 - Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells.
Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, Medina D. Goepfert TM, et al. FASEB J. 2000 Nov;14(14):2221-9. doi: 10.1096/fj.00-0165com. FASEB J. 2000. PMID: 11053243 - Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Deng CX, Scott F. Deng CX, et al. Oncogene. 2000 Feb 21;19(8):1059-64. doi: 10.1038/sj.onc.1203269. Oncogene. 2000. PMID: 10713690 Review. - The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
Moynahan ME. Moynahan ME. Oncogene. 2002 Dec 16;21(58):8994-9007. doi: 10.1038/sj.onc.1206177. Oncogene. 2002. PMID: 12483515 Review.
Cited by
- CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.
Yuan X, Hao X, Chan HL, Zhao N, Pedroza DA, Liu F, Le K, Smith AJ, Calderon SJ, Lieu N, Soth MJ, Jones P, Zhang XH, Rosen JM. Yuan X, et al. JCI Insight. 2024 Sep 17;9(20):e182621. doi: 10.1172/jci.insight.182621. JCI Insight. 2024. PMID: 39287984 Free PMC article. - CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.
Yuan X, Hao X, Chan HL, Zhao N, Pedroza DA, Liu F, Le K, Smith AJ, Calderon SJ, Lieu N, Soth MJ, Jones P, Zhang XH, Rosen JM. Yuan X, et al. bioRxiv [Preprint]. 2024 Apr 27:2024.04.25.590983. doi: 10.1101/2024.04.25.590983. bioRxiv. 2024. PMID: 38712292 Free PMC article. Updated. Preprint. - Benzophenone-3 alters expression of genes encoding vascularization and epithelial-mesenchymal transition functions during Trp53-null mammary tumorigenesis.
Morozova E, Kariagina A, Busch C, Schwartz RC. Morozova E, et al. Food Chem Toxicol. 2024 Apr;186:114540. doi: 10.1016/j.fct.2024.114540. Epub 2024 Feb 20. Food Chem Toxicol. 2024. PMID: 38387520 - Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM. Zhao N, et al. J Clin Invest. 2023 Dec 15;133(24):e172503. doi: 10.1172/JCI172503. J Clin Invest. 2023. PMID: 37874652 Free PMC article. - ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G, Romero Y, Thevarajan I, Zolkiewska A. Wang G, et al. Oncoimmunology. 2022 Dec 16;12(1):2158006. doi: 10.1080/2162402X.2022.2158006. eCollection 2023. Oncoimmunology. 2022. PMID: 36545255 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous